Jan 31 | News
NEW YORK (AP) — Pfizer said today that its fourth-quarter profit fell by half due to one-time charges and a drop in U.S. revenue, which was hurt by blockbuster cholesterol drug Lipitor losing patent protection.
|
Jan 27 | News
Pfizer Inc. announced today that the FDA has accepted its New Drug Application (NDA) for standard review of bosutinib as a treatment option for adult patients with previously treated Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML).
|
Jan 25 | News
Watson CEO Paul Bisaro said that Pfizer’s strategy to keep its market share of Lipitor may boost revenue without aiding profit, Bloomberg reported.
|
Jan 25 | News
In final guidance issued Wednesday, the National Institute for Health and Clinical Excellence recommended the use of Bristol-Myers Squibb and Pfizer's Eliquis (apixaban) for the prevention of venous thromboembolism in adults who have undergone total hip replacement or total knee replacement surgery.
|
Jan 17 | News
NEW YORK (AP) — Pfizer and Medivation are ending the development of a potential Alzheimer's disease treatment after the drug yielded disappointing results in a late-stage clinical study.
|
Jan 16 | Articles
Vaccines continue to be one of the brighter spots for pharmaceutical companies in the current market, and revenues for vaccine products are expected to continue their double-digit growth in the future.
|
Jan 11 | News
California-based NantWorks, LLC, announced plans today to locate a new pharmaceutical manufacturing plant in Terre Haute, Indiana, creating up to 234 new jobs by 2016.
|
Jan 9 | News
Pfizer Inc., has entered an agreement with drug developer SFJ Pharma Ltd. II to conduct a late-stage trial in Asia of Pfizer's potential kidney cancer treatment axitinib.
|
Jan 5 | News
SAN DIEGO (AP) — Genetic analysis instrument maker Illumina Inc. is hiring Marc Stapley of Pfizer as its chief financial officer.
|
Dec 31 2011 | News
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of the Company’s pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for...
|